186 results about "ARDs - Acute respiratory distress syndrome" patented technology

The invention relates to therapeutic antisense oligonucleotides directed against genes coding for phosphodiesterase (PDEs) and the use of these in combination. These antisense oligonucleotides may be used as analytical tools and/or as therapeutic agents in the treatment of disease associated with reduced cellular cAMP in a patient, such as inflammatory diseases of the respiratory tract including, for example, asthma, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome, bronchitis, chronic bronchitis, silicosis, pulmonary fibrosis, lung allograft rejection, allergic rhinitis and chronic sinusitis as well as other conditions in which an increase in cyclic AMP or a decrease in PDE levels is beneficial.

The invention provides novel methods for treating disease based upon the medicinal use of lipids and phospholipids covalently bound to physiologically acceptable monomers or polymers. Phosphatidylethanolamine moieties conjugated to physiologically acceptable monomers and polymers (PE conjugates) manifest an unexpectedly wide range of pharmacological effects, including stabilizing cell membranes; limiting oxidative damage to cell and blood components; limiting cell proliferation, cell extravasation and (tumor) cell migratory behavior; suppressing immune responses; and attenuating physiological reactions to stress, as expressed in elevated chemokine levels. The surprisingly manifold pharmacological properties of the PL-conjugates allow for the invention, disclosed herein, of novel methods for the treatment of a diverse range of disease states, including obstructive respiratory disease, including asthma; colitis and Crohn's disease; central nervous system insult, including blood brain barrier compromise, ischemic stroke, and multiple sclerosis; contact dermatitis; psoriasis; cardiovascular disease, including ischemic conditions and prophylaxis for invasive vascular procedures; cellular proliferative disorders, including anti-tumor vasculogenesis, invasiveness, and metastases; anti-oxidant therapy; hemolytic syndromes; sepsis; acute respiratory distress syndrome; tissue transplant rejection syndromes; autoimmune disease; viral infection; and hypersensitivity conjunctivitis. The therapeutic methods of the invention include administration of phosphatidylethanolamine bound to carboxymethylcellulose, heparin, hyaluronic acid, polyethylene glycol, and Polygeline (haemaccel). Disclosed herein are also new compounds comprised of phospholipid moieties bound to low molecular weight monomers and dimers, including mono- and disaccharides, carboxylated disaccharides, mono- and dicarboxylic acids, salicylates, bile acids, and fatty acids.

The present invention relates generally to the field of prophylaxis and therapy for inflammatory and/or fibrotic diseases which include responses to injuries. In particular, the present invention is related to agents that can bind or complex copper such as thiomolybdate, and to the use of these agents in the prevention and treatment of inflammatory and/or fibrotic diseases. Exemplary thiomolybdates include mono-, di-, tri- and tetrathiomolybdate; these agents are administered to patients to prevent and/or treat inflammatory and/or fibrotic diseases, such as pulmonary disease including pulmonary fibrosis and acute respiratory distress syndrome, liver disease including liver cirrhosis and hepatitis C, kidney disease including renal interstitial fibrosis, scleroderma, cystic fibrosis, pancreatic fibrosis, keloid, secondary fibrosis in the gastrointestinal tract, hypertrophic burn scars, myocardial fibrosis, Alzheimer's disease, retinal detachment inflammation and/or fibrosis resulting after surgery, and graft versus host and host versus graft rejections.

The invention discloses a neutrophilic granulocyte elastase inhibitor of which the active ingredient is a compound with a pentacyclic triterpene structure. The inhibitor can be used for preparing a medicament or health-care food for treating or preventing diseases with neutrophilic granulocyte elastase as an action way. The diseases with the neutrophilic granulocyte elastase as an action way include acute lung injury, acute respiratory distress syndrome, systemic inflammatory response syndrome and cystic fibrosis diseases. As the active ingredient of the neutrophilic granulocyte elastase inhibitor disclosed by the invention, the compound with the pentacyclic triterpene structure can be extracted and separated from a natural product or can be prepared from a natural product through chemical synthesis, and has the advantages of being wide in sources, safe and effective.

The present invention relates to the use of modified factor VI[ for manufacture of medicaments for treatment of Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome (ARDS) in humans.

The invention belongs to the field of traditional Chinese medicine preparation, and relates to a dipeptide compound represented by a formula I and a new use of the dipeptide compound in preparation of anti-complement drugs. According to the present invention, the dipeptide compound is separated from the ethyl acetate extraction position of the ethanol extract of the dry whole herb Viola yedoensis Makino, and results confirm that the dipeptide compound provides inhibition effects for the classical pathway and the alternative pathway of the complement system, wherein the inhibition effect on the classical pathway (CH50) is 0.21-0.23 mg/ml, and the inhibition effect on the alternative pathway (AP50) is 0.33-0.41 mg/ml; and the dipeptide compound can be adopted as the drug active component to be adopted to prepare the anti-complement drug so as to be further adopted to treat systemic lupus erythematosus, rheumatoid arthritis, acute respiratory distress syndrome and other diseases initiated by excessive activation of the complement system.

The invention belongs to the field of traditional Chinese medicine preparation, and relates to an alkaloid compound represented by a formula I and a new use of the alkaloid compound in preparation of anti-complement drugs. According to the present invention, the alkaloid compound is separated from the ethyl acetate extraction position of the ethanol extract of the dry whole herb Viola yedoensis Makino, and results confirm that the alkaloid compound provides inhibition effects for the classical pathway and the alternative pathway of the complement system, wherein the inhibition effect on the classical pathway (CH50) is 0.16-0.31 mg/ml, and the inhibition effect on the alternative pathway (AP50) is 0.26-0.46 mg/ml; and the alkaloid compound can be adopted as the drug active component to be adopted to prepare the anti-complement drug so as to be further adopted to treat systemic lupus erythematosus, rheumatoid arthritis, acute respiratory distress syndrome and other diseases initiated by excessive activation of the complement system.

The present invention relates to a use of a pharmaceutical composition in the manufacture of medicament for treating related diseases caused by endotoxemia. The pharmaceutical composition comprises 3-methyl-1-phenyl-2-pyrazolin-5-one or pharmaceutically acceptable salt thereof and borneol. The diseases include, but are not limited to, systemic inflammatory response syndrome, sepsis, severe sepsis, septic shock, sepsis related disseminated intravascular coagulation, acute lung injury, acute respiratory distress syndrome, multiple organ failure syndrome, septic brain injury and inflammatory lung injury caused by other reasons, including but not limited to bacterial pneumonia.

Embodiments of the present invention encompass systems and methods for administering intrathoracic pressure and cooling treatments to patients suffering from or at risk of developing heart failure, cardiac arrest, sepsis, shock, acute respiratory distress syndrome, polytrauma, head disease, elevated hepatic or portal vein pressures, bleeding during abdominal, head and neck surgery, or insufficient circulation during open heart surgery.

The injection preparation for treating acute lung injury and acute respiratory distress syndrome is bacteria-free freeze dried powder for injection with Sivelestat as active component, stuffing frame agent, co-solvent and pH regulator. It has improved water solubility of Sivelestat and improved medicine stability.

Polypeptides are identified through an assay based on inhibiting AP-I signalling activity and others to treat acute respiratory distress syndrome (ARDS) and clinical disorders associated with the development of ARDS.

A method of cellular therapy for a lung disease or condition in a subject is disclosed, wherein the method involves the administration of multipotent epithelial stem cells derived from amnion tissue (AECs). In a particular application, the method is used for the treatment of lung diseases and conditions such as chronic lung diseases including chronic obstructive pulmonary disease (COPD), acute lung conditions such as acute respiratory distress syndrome (ARDS), and ventilator associated lung injury (VALI).

The present invention relates to method of treating a patient with a condition involving increased vascular permeability or increased angiogenesis comprising administering to the patient a therapeutically effective amount of PEDF, PEDF 44 AA peptide, a homolog of the PEDF 44 AA peptide, a homolog of the PEDF 44 AA peptide wherein amino acid residues glutamate the (101) amino acid position, isoleucine at the (103) amino acid position, leucine at the (112) and serine at the (115) amino acid position are unchanged, or an agent that activates the PEDF receptor. Conditions for treatment include, but are not limited to, sepsis acute respiratory distress syndrome, nephrotic syndrome, diabetic neuropathy, preproliferative diabetic retinopathy, cancer or proliferative diabetic retinopathy.

The invention discloses a method and system for predicting mortality of acute respiratory distress syndrome (ARDS). The method comprises obtaining medical data of ARDS patients; adopting a machine learning method to perform model training according to the obtained medical data and obtaining an ARDS mortality prediction model; adopting the ARDS mortality prediction model to predict an object to bepredicted to obtain a prediction result of the mortality of the ARDS. The machine learning method is adopted to train the ARDS mortality prediction model, then the ARDS mortality prediction model is adopted to predict the mortality of the ARDS patients, and the machine learning is applied to the mortality prediction of the ARDS patients. The mortality of The ARDS patients can be accurately and objectively predicted by the model trained by the machine learning to provide clinicians with more effective and feasible prediction information, and the method and system can be widely used in the fields of medical data mining.

This invention is directed to methods of preventing or treating diseases or conditions of the lungs associated with excessive cell proliferation, remodeling, inflammation, vasoconstriction, bronchoconstriction, airway hyperreactivity and edema. Particularly, this invention is directed to methods of treating pulmonary diseases such as asthma; chronic obstructive pulmonary disease; respiratory tract illness caused by respiratory syncytial virus; pulmonary arterial hypertension; acute respiratory distress syndrome and ventilator induced lung injury; cystic fibrosis; bronchiectasis; alpha-1-antitrypsin deficiency; rhinitis; rhinosinusitis; primary ciliary dyskinesia; pneumonia; bronchiolitis caused by agents other than respiratory syncytial virus; and interstitial lung disease including lymphangioleiomyomatosis; idiopathic pulmonary fibrosis; obliterative bronchiolitis or bronchiolitis obliterans organizing pneumonia due to lung transplantation or HSCT; nonspecific interstitial pneumonia; cryptogenic organizing pneumonia; acute interstitial pneumonia; respiratory bronchiolitis-associated interstitial lung disease; or pulmonary sarcoidosis. The method comprises administering to a subject an effective amount of a rho kinase inhibitor compound to treat the disease.

The invention provides a breathing parameter adjusting method and a device of breathing support equipment, and the breathing support equipment. The method comprises the following steps of: acquiring basic information of a patient and breathing parameters of a breathing support equipment in real time during ventilation, wherein the basic information of the patient at least comprises blood pressure,blood oxygen saturation and symptoms, and the breathing parameters at least comprise inhaled oxygen concentration and end-tidal positive pressure; and adjusting the breathing parameters by using corresponding parameter adjustment strategies according to the basic information and the breathing parameters, wherein the parameter adjustment strategies comprise an acute respiratory distress syndrome adjustment strategy, a chronic obstructive pulmonary disease adjustment strategy, an hypotension adjustment strategy and a stretching index adjustment strategy. The method is capable of automatically,rapidly and accurately adjusting the parameters of the breathing support equipment, thereby rapidly correcting the hypoxia oximetry, thereby facilitating the ventilation auxiliary treatment of patients and improving the off-line success rate and safety.

The complement activation is a risk factor for the morbidity and mortality of novel coronavirus-19 (COVID-19) patients, and is mediated by a highly immunopathogenic nucleocapsid protein (N) in which severe acute respiratory distress syndrome-related coronavirus 2 (SARS-CoV-2) binds to serine protease MASP-2 in the agglutinin pathway of complement activation. According to the invention, a dominant antibody with anti-SARS-CoV-2 virus N protein is separated and identified from a rapidly recovered COVID-19 convalescent person, and the antibody has high binding affinity. In addition, based on the cleavage activity of the complement protease MASP-2 on a specific fluorescence quenching peptide substrate, the invention further develops a virus-free complement hyper-activation analysis method.